医学
近距离放射治疗
泌尿生殖系统
前列腺
前列腺癌
临床试验
肿瘤科
放射治疗
内科学
前瞻性队列研究
剂量分馏
总体生存率
生活质量(医疗保健)
挽救疗法
前列腺切除术
外照射放疗
危险分层
放射科
直肠炎
临床研究阶段
毒性
队列
生存分析
疾病
前列腺特异性抗原
临床终点
作者
Abhishek Ashok Solanki,William Adams,James A. Proudfoot,Kristin G. Baldea,Guliz Akdas Barkan,Alec M. Block,Neil Bipinchandra Desai,Ahmer V Farooq,Michael R. Folkert,Aurélie Garant,Alex Gorbonos,Gopal Nand Gupta,Hyejoo Kang,Eileen M. Kelly,Steven Kregel,Stanley L. Liauw,C. Luminais,Michael L. Mysz,Marcus Lee Quek,Timothy Norman Showalter
摘要
Purpose Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. Methods F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS). Results Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence. Conclusion DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.
科研通智能强力驱动
Strongly Powered by AbleSci AI